Aubuchon Neil William
Chief Commercial Officer
Aubuchon Neil William has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Mar 10, 2026.
On the most recent filing, Aubuchon Neil William is listed as Chief Commercial Officer at Viking Therapeutics, Inc. Inside the rolling window, Aubuchon Neil William reported 1 open-market purchase totaling $150K in VKTX and no open-market sales.
Companies traded
Other insiders at VKTX
Insider Buying
$150K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Aubuchon Neil William made?
Aubuchon Neil William has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2026.
Which companies does Aubuchon Neil William trade?
Aubuchon Neil William has filed SEC Form 4 disclosures for 1 company, including VKTX.
When was Aubuchon Neil William's most recent SEC Form 4 filing?
Aubuchon Neil William's most recent SEC Form 4 filing on Tracefour is dated Mar 10, 2026.
What is Aubuchon Neil William's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Aubuchon Neil William is listed as Chief Commercial Officer.
What is Aubuchon Neil William's total buy and sell value in the current window?
Inside the rolling retention window, Aubuchon Neil William bought $150K and sold $0 based on SEC Form 4 filings.
What was Aubuchon Neil William's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 4,475 VKTX shares on 2026-03-10, worth $150K, per SEC Form 4 filings.